Five things for pharma marketers to know: Thursday, March 16, 2017


1. Marathon Pharmaceuticals plans to sell Emflaza, the Duchenne muscular dystrophy drug under scrutiny for its high price tag, to PTC Therapeutics for $140 million in cash and stock. Marathon priced Emflaza at $89,000 per year at launch, though generic versions of the drug can be imported for $1,000 or less. (Reuters)

2. Emma Walmsley, who takes over as CEO of GlaxoSmithKline later this month, will earn less money than her predecessor, Andrew Witty. The company attributed the discrepancy to  her relative lack of experience. She is the first woman to lead a drugmaker of this size. (Bloomberg)

3. President Donald Trump told Fox News' Tucker Carlson that he is considering legislation to allow Medicare to negotiate drug prices. "We're going to get drug prices so far lower than they are now your head will spin," Trump said. (Axios)

4. The number of TV ads encouraging health insurance enrollment in 2013 and 2014 led to higher rates of insurance, a study found. State-sponsored ads were most likely to lead to declines in uninsurance in the regions where they aired. (Health Affairs)

5. The FDA said patients who have undergone cholecystectomy should not take Allergan's irritable bowel syndrome drug Viberzi. The regulator has received 120 reports of serious pancreatitis or deaths in patients taking the drug since May 2015, when it was first approved. (MedPage Today)